Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia

Full text
Author(s):
Cle, Diego V. [1, 2] ; Santana-Lemos, Barbara [1, 2] ; Tellechea, Maria Florencia [1] ; Prata, Karen L. [1] ; Orellana, Maristela D. [1] ; Covas, Dimas T. [2, 1] ; Calado, Rodrigo T. [1, 2]
Total Authors: 7
Affiliation:
[1] Sao Paulo Res Fdn FAPESP, Ctr Cell Based Therapy, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Ribeir Preto Sch Med, Dept Internal Med, BR-14049 Ribeirao Preto, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: CYTOTHERAPY; v. 17, n. 12, p. 1696-1705, DEC 2015.
Web of Science Citations: 9
Abstract

Background aims. For patients with aplastic anemia (AA) who are refractory to anti-thymocyte globulin (ATG) and cyclosporine, a second course of immunosuppression is successful in only one-fourth to one-third of cases. Methods. We conducted a phase 1/2 study to evaluate the addition of two to five weekly intravenous infusions of allogeneic unrelated non human leukocyte antigen matched bone marrow derived mesenchymal stromal cells (MSCs) (median, 2.7 x 10(6) cells/kg/infusion; range, 1.3-4.5) to standard rabbit ATG and cyclosporine in nine patients with refractory or relapsed AA. Results. After a median follow-up of 20 months, no infusion-related adverse event was observed, but four deaths occurred as the result of heart failure and bacterial or invasive fungal infections; only two patients achieved partial hematologic responses at 6 months. We failed to demonstrate by fluorescence in situ hybridization or variable number tandem repeat any MSC engraftment in patient marrow 30, 90 or 180 days after infusions. Conclusions. Infusion of allogeneic MSCs in AA is safe but does not improve clinical hematologic response or engraft in recipient bone marrow. This study was registered at clinicaltrials.gov, identifier: NCT01297972. (AU)

FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC